AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01757899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline Arm
Description: Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc \[methylprednisolone + diluting fluid\], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
Study NCT02409186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotuzumab
Description: 400mg/w，d1, week 1-7
Study NCT02409186 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
Study NCT02409186 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
Study NCT02409186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiotherapy Paclitaxel
Description: 45 mg/m2, d1, week 1-7
Study NCT02409186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chemoradiotherapy Paclitaxel
Description: 45 mg/m2, d1, week 1-7
Study NCT02409186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiotherapy Cisplatin
Description: 20 mg/m2, d1, week 1-7
Study NCT02409186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chemoradiotherapy Cisplatin
Description: 20 mg/m2, d1, week 1-7
Study NCT02409186 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 400mg/w，d1, week 1-7
Study NCT04611984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocision
Description: Piezocisions were performed on the mesial and distal sides of the right maxillary canines. Then canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
Study NCT04611984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The mesial and distal sides of the left maxillary canines served as controls and canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
Study NCT04306640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sagittal Cervical Posture Corrective Orthotic Device
Description: The subjects in the traction group will receive the deneroll extension traction. The subjects will be asked to lie supine on the ground with their legs straight, upper arms by their sides and forearms gently folded across their trunk. The therapist will place the apex of the denneroll either in the mid cervical region or the lower cervical region depending on the apex of cervical curvature deformity of each subject. Initially, participants begin with three minutes of sustained denneroll extension traction and progressed to the goal of 20 min per session with one to two additional minutes per session
Study NCT04306640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sagittal Cervical Posture Corrective Orthotic Device
Description: The subjects in the traction group will receive the deneroll extension traction. The subjects will be asked to lie supine on the ground with their legs straight, upper arms by their sides and forearms gently folded across their trunk. The therapist will place the apex of the denneroll either in the mid cervical region or the lower cervical region depending on the apex of cervical curvature deformity of each subject. Initially, participants begin with three minutes of sustained denneroll extension traction and progressed to the goal of 20 min per session with one to two additional minutes per session
Study NCT00567580 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PBRT
Description: 1.8 Gy per fraction once daily, 5 days a week totaling 64.8-70.2 Gy. 3D-CRT or IMRT required.
Study NCT00567580 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PBRT
Description: 1.8 Gy per fraction once daily, 5 days a week totaling 64.8-70.2 Gy. 3D-CRT or IMRT required.
Study NCT00567580 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PLNRT
Description: 1.8 Gy per fraction once daily, 5 days a week, totaling 45 Gy. 3D-CRT or IMRT required.
Study NCT00567580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AA
Description: Antiandrogen (AA) therapy can be either 250 mg flutamide by mouth three times a day or 50 mg bicalutamide by mouth once a day.
Study NCT00567580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: Luteinizing hormone-releasing hormone (LHRH) agonist can be any analog approved by the FDA (or by Health Canada for Canadian institutions) and may be given in any possible combination such that the total LHRH treatment time is 4-6 months. LHRH analogs are administered with a variety of techniques, including subcutaneous insertion of a solid plug in the abdominal wall, intramuscular injection, and subcutaneous injection.
Study NCT06150690 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: The participants did not receive any study-specific intervention
Study NCT04423328 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: acupressure
Description: self-acupressure
Study NCT04253600 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Risk profile screening questionnaire
Description: Families will be asked to complete a LimeSurvey questionnaire that aims at evaluating general risk profiles associated with DLD (e.g., no elevated risk, behavioral risk, environmental risk, familial risk), as well as our exclusion criteria (e.g., hearing deficit).
Study NCT04253600 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Investigation of the neural correlates of DLD using Magnetic Resonance Imagery (MRI)
Description: MRI data acquisition will take place during natural sleep in infants aged from 6 to 12 months. First, families will have to complete a security questionnaire to make sure that neither the children nor the accompanying parent have any known contraindication preventing the MRI session and that none of them is wearing any ferro-magnetic elements. Then, families will be welcomed in a calm and child-friendly environment where we will propose them some preparatory games known to facilitate sleep in children. MRI protocol will comprise structural and functional images and won't exceed 30 minutes.
Study NCT04253600 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online investigation of predictive factors associated with DLD and LANCOM app development
Description: Parents will be asked to complete a series of online questionnaires every six months. Questionnaires will be created on LimeSurvey and will include different questionnaires, scales, and observations that aim at evaluating children's development, and especially language development, as well as parental and environmental characteristics.
Study NCT04253600 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individual behavioral and cognitive assessment
Description: Individual cognitive and behavioral assessment will be scheduled once a year, around the child's birth date, and will comprise an extensive battery of standardized evaluation appropriate for the child's age. This individual evaluation will focus on several developmental aspects including language, psychomotor, behavioral and cognitive development, as well as executive and socio-emotional functioning, depending on the age of the children. Evaluations will be adapted to each child's specific profile, while respecting the following administration rules: (1) we will prioritize language development testing, (2) testing sessions will be adapted to each child's pace and possibilities, (3) if a child does not want to take part in the assessment, feels tired, or does not seem to be comfortable with the investigator, tests won't be administered.
Study NCT04253600 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Automated analysis of language development and environment
Description: Following the individual assessment, families will be asked to record their child's language environment over a 2-days' timeframe using the LENA® device, a small wearable device allowing for large-scale all-day audio recording and automated vocal analyses of speech segments. An automatic analysis of the recordings, performed by the LENA pro software algorithms, will provide amongst others, a direct and natural measure of the child's number of vocalizations, adult word counts, conversational turns, duration of exposure to electronic media versus to meaningful language. Data acquisition will take place once a year following our sample selection, with a required recording time per day ranging from 12 to 16 hours.
Study NCT02021526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Triheptanoin (C7 oil) is a 7-carbon medium chain triglyceride.
Study NCT01924910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 250,000 IU cholecalciferol as single, oral dose
Description: 250,000 IU cholecalciferol (vitamin D3) provided as a single oral dose.
Study NCT01924910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04181307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BE-EHR module
Description: The BE-EHR module includes six components: 1) a tailored advisory for patients over 75 with diabetes, 2) medication refill protocol with information on Choosing Wisely guidelines, 3) pre-population of the medication preference list with metformin, 4) lab result protocol with information on Choosing Wisely guidelines, 5) peer comparisons regarding performance meeting guidelines, and 6) media campaign with information about Choosing Wisely guidelines. The set of nudges is referred to collectively as the BE-EHR module.
Study NCT01058746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: restrictive perioperative fluid management
Description: Normosol or equivalent solution 0.5 ml/kg/fasted hour IV (8am to time of induction) during induction of Anesthesia. Maintenance IV Normosol or equivalent solution at 6 ml/kg/operative hour. Blood loss to be replaced volume: volume with colloid until transfusion criteria met. Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) at the discretion of the Anesthesiologist to maintain patient hemodynamic stability.
Study NCT01058746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal perioperative fluid management
Description: Normosol or equivalent solution 0.5 ml/kg/fasted hr IV (8am to time of induction) of Anesthesia. Maintenance IV Normosol or equiv solution at 6 ml/kg/oper hr. At randomiz to the Liberal arm in the OR, an addit bolus of Normosol or equiv solution 1.5 ml/kg/fasted hr IV (8am to time of induction) will be given to bring the total to Normosol or equiv solution 2ml/kg/fasted hr IV (8am to time of induction). Pt will get an addit bolus of Normosol or equivalent solution 6ml/kg/oper hr. Maintenance IV Normosol or equivalent solution will then commence at 12ml/kg/operative hr with maximum of 1000 ml/operative hr. Blood loss replaced volume: with colloid, until transfusion criteria met (Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) used at the discretion of the Anes to maintain pt hemodynamic stability. Addit fluid boluses of 250ml Normosol or equivalent solution for urine output less than 1ml/kg for 2 hrs.
Study NCT03336229 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise intervention
Description: Graduated walking programme, strengthening exercises and respiratory muscle training.
Study NCT03182855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.
Study NCT03182855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cangrelor Tetrasodium
Description: Intravenous ADP-receptor blocker. Administered after hospital arrival in the catheterization laboratory.
Study NCT04196621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High viscous artificial tears
Description: Instillation of one drop high viscous artificial tears
Study NCT04196621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low viscous artificial tears
Description: Instillation of one drop low viscous artificial tears
Study NCT00133705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 5mg/day by mouth for 6 months
Study NCT00133705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inert Capsule
Description: sugar pill
Study NCT03320005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training group
Description: Resistive exercises for legs and arms
Study NCT01765400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel 10 mg daily x 2 weeks
Study NCT01765400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 mg daily x 2 weeks
Study NCT04033640 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SD Biosensor STANDARD G6PD Test
Description: The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care (POC) setting. The test is intended to aid in the identification of people with G6PD deficiency.~The test is currently not licensed for use in Brazil and is considered an investigational product.
Study NCT04033640 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pointe Scientific Test Kit
Description: The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
Study NCT04033640 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HemoCue System
Description: The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
Study NCT04033640 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Complete blood count (CBC)
Description: In Manaus, hemoglobin concentration was determined by CBC using an automated hematology analyzer (Sysmex KX-21N).
Study NCT01651988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamina-Propofol Combination
Description: After randomization to the study group, the patients were given:~Procedures \< 10 minutes~1. Ketamine-Propofol Combination KETOFOL 1:1~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: cc/kg 0.04 (50 mg/cc = 2 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~2. Ketamine-Propofol Combination KETOFOL 1:2~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: 0.02 cc/kg (50 mg/cc = 1 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~Procedures > 10 minutes~In addition to the initial bolus, an infusion was started:~KETOFOL 1:1~20 cc of propofol (10 mg/cc = 200 mg in total) 4 cc of ketamine (50 mg/cc = 200 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 66 cc 0.9% SSN~KETOFOL 1:2~20 cc of propofol (10 mg/cc = 200 mg in total) 2 cc of ketamine (50 mg/cc = 100 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 68 cc 0.9% SSN~Speed infusion:~0,03cc/kg/min
Study NCT01651988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamina-Propofol Combination
Description: After randomization to the study group, the patients were given:~Procedures \< 10 minutes~1. Ketamine-Propofol Combination KETOFOL 1:1~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: cc/kg 0.04 (50 mg/cc = 2 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~2. Ketamine-Propofol Combination KETOFOL 1:2~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: 0.02 cc/kg (50 mg/cc = 1 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~Procedures > 10 minutes~In addition to the initial bolus, an infusion was started:~KETOFOL 1:1~20 cc of propofol (10 mg/cc = 200 mg in total) 4 cc of ketamine (50 mg/cc = 200 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 66 cc 0.9% SSN~KETOFOL 1:2~20 cc of propofol (10 mg/cc = 200 mg in total) 2 cc of ketamine (50 mg/cc = 100 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 68 cc 0.9% SSN~Speed infusion:~0,03cc/kg/min
Study NCT03973320 — intervention group
Intervention type: OTHER
Intervention: Chart Review
Description: This is a chart review to determine if hypotensive neuraxial anesthesia is associated with worse outcomes in Primary Total Hip Arthroplasty patients.
Study NCT03378960 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole 20mg
Study NCT04225767 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Calcium electroporation
Description: Patients with cutaneous or subcutaneous malignant tumours will be treated with calcium electroporation, i.e. intratumoral injection of calcium followed by electroporation by electric pulses applied directly to the tumor.
Study NCT01690533 — intervention group
Intervention type: DRUG
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Patients treated with Moxifloxacin in daily clinical practice
Study NCT03514576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide 0.3 MG/ML
Description: See arm description
Study NCT03514576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Meal tolerance test (MTT)
Description: Subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
Study NCT02642757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AUDIT brief intervention
Description: Intervention will be provided following the Chilean ministry of health implementation manual on the AUDIT associated brief intervention. The pamphlet on alcohol use will be provided to participants.
Study NCT02642757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pamphlet on alcohol use
Description: Only the pamphlet on alcohol use will be provided (the same received by participants on the intervention group). This is not an active intervention based on the current literature.
Study NCT02642757 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pamphlet on alcohol use
Description: Only the pamphlet on alcohol use will be provided (the same received by participants on the intervention group). This is not an active intervention based on the current literature.
Study NCT02682056 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Microneedle patch
Description: The microneedle patch will collect interstitial fluid to be tested for glucose level. The microneedles are made from biocompatible polymers or metal. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
Study NCT02682056 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intravenous (IV) catheter
Description: The intravenous (IV) catheter will collect venous blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
Study NCT02682056 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lancet
Description: The lancet will collect capillary blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
Study NCT04329884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cooled RFA treatment with COOLIEF* device
Description: Patients who are randomized to receive CRFA will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
Study NCT04329884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-articular corticosteroid injection
Description: Patients who are randomized to receive intra-articular corticosteroid injections will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
Study NCT02957838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C18:0
Description: Receives 24g of C18:0 in a low-fat banana milkshake.
Study NCT02957838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mock
Description: Low fat banana milkshake without C18:0 supplement.
Study NCT03314090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silicone Gels
Description: silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day. The amount used being similar in size to a grain of rice.
Study NCT03134040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives (Rebate)
Study NCT03134040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives (Donation)
Study NCT03134040 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback
Study NCT00569179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34 Reagent System
Description: Alloreactive NK cells will be purified by a two-step immunomagnetic selection (CD3 depletion followed by CD56 selection) using the CliniMACS device.